Setipiprant

Generic Name
Setipiprant
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H19FN2O3
CAS Number
866460-33-5
Unique Ingredient Identifier
BHF20LA2GM
Background

Setipiprant has been investigated for the treatment of Seasonal Allergic Rhinitis.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Phase 2
Completed
Conditions
Alopecia
Interventions
Drug: Placebo
Drug: Setipiprant
Drug: Finasteride
First Posted Date
2016-05-24
Last Posted Date
2019-04-05
Lead Sponsor
Allergan
Target Recruit Count
169
Registration Number
NCT02781311
Locations
🇺🇸

DeNova Research, Chicago, Illinois, United States

🇺🇸

Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States

🇺🇸

Heartland Research Associates, LLC, Wichita, Kansas, United States

and more 14 locations

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Setipiprant
Drug: Placebo
First Posted Date
2010-10-21
Last Posted Date
2018-07-09
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
438
Registration Number
NCT01225315
Locations
🇵🇱

Clinical Investigative Site # 5501, Lodz, Poland

🇺🇸

Clinical Investigative Site # 6215, New Orleans, Louisiana, United States

🇺🇸

Clinical Investigative Site 6202, Knoxville, Tennessee, United States

and more 94 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy